COIOSDeep risk insights through multi-disciplinary research across the globe
woman standing surrounded by exercise equipment
Item new Peer-reviewed Added

Trevogrumab, with or without garetosmab, against muscle loss on semaglutide in obesity

A phase 2 trial in 975 adults with obesity tested GDF8 and activin A antibodies against semaglutide-related lean mass loss.

COURAGE tested antibodies blocking GDF8 (trevogrumab) and activin A (garetosmab) for muscle loss during semaglutide-induced weight loss. The phase 2, double-blind, placebo-controlled trial randomised 975 adults with obesity at 60 US sites. Part A added placebo, trevogrumab 200 or 400 mg, or trevogrumab plus garetosmab to semaglutide for 26 weeks. Part B added placebo or trevogrumab 25 or 75 mg to semaglutide for 52 weeks. With semaglutide plus placebo, lean mass fell substantially by week 26. Endpoints were lean mass, fat mass and bodyweight, not muscle strength or function, and all sites were in the US.

Why it is interesting: Lean mass loss accompanies the rapid weight loss seen with GLP-1 receptor agonists. This large randomised trial tests whether blocking two negative regulators of muscle mass can offset that loss.

Source
The Lancet, 11 November 2026
Paper
Trevogrumab (anti-GDF8) with or without garetosmab (anti-activin A) for prevention of muscle loss during semaglutide-induced weight reduction in people with obesity (COURAGE): a two-part, phase 2, double-blind, placebo-controlled, randomised trial
Authors
Mosenzon O, Rosenstock J, Raya JG, Grimsby JS, Calle RA, Cannon K et al.
DOI
10.1016/S0140-6736(26)01953-7
Type
Peer-reviewed article
Design
Two-part phase 2 double-blind placebo-controlled RCT, 60 US sites, n=975, 26-52 weeks, 2024-2025
Verdict
New finding
Driver
Innovation in treatment
Driver
Obesity, diabetes and GLP-1

Other drivers in Tomorrow's world